### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: G01N 27/327, 27/333	A1	(11) International Publication Number: WO 98/55854
		(43) International Publication Date: 10 December 1998 (10.12.98)
<ul> <li>(21) International Application Number: PCT/AU</li> <li>(22) International Filing Date: 4 June 1998 (</li> <li>(30) Priority Data: PO 7171 4 June 1997 (04.06.97)</li> <li>(71) Applicants (for all designated States except US): TRALIAN MEMBRANE AND BIOTECHN RESEARCH INSTITUTE [AU/AU]; 126 Grevill Chatswood, NSW 2067 (AU). THE UNIVERS SYDNEY [AU/AU]; Sydney, NSW 2006 (AU).</li> <li>(72) Inventor; and (75) Inventor/Applicant (for US only): WIECZOREI [AU/AU]; 5 Peach Tree Road, North Ryde, NS (AU).</li> <li>(74) Agent: F.B. RICE &amp; CO.; 605 Darling Street, Balman 2041 (AU).</li> <li>(4) Title: IMPROVED BIOSENSOR</li> </ul>	(04.06.9  A  NOLOG BIE Street SITY O	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published  With international search report.

#### (57) Abstract

The present invention provides a membrane based biosensor. The biosensor includes an electrode and a passivating layer bound to the electrode. A lipid membrane incorporating ionophores, the conductivity of the membrane being dependent on the presence or absence of an analyte, is bound to the passivating layer in a manner such that an ionic reservoir exists between the membrane and the passivating layer. Reservoir spanning molecules spanning the ionic reservoir are also included. These molecules are covalently attached at one end to the membrane and at the other to the passivating layer. The incorporation of this passivating provides greater stability to the sensor.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL AM AT AU AZ BA BB BE BF BG BJ BR CA CF CG CM CN CU CZ DE DK EE	Albania Armenia Austria Austria Australia Azerbaijan Bosnia and Herzegovina Barbadoe Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Cuba Czech Republic Germany Denmark Estonia	ES FI FR GA GB GGN GR HU IE IL IS TI P KE KG KP KZ LC LI LK	Spain Finland France Gabon United Kingdom Georgia Ghana Guinea Greece Hungary Ireland Israel Iceland Italy Japan Kenya Kyrgyzstan Democratic People's Republic of Korea Republic of Korea Kazakstan Saint Lucia Liechtenstein Sri Lanka Liberia	LS LT LU LV MC MD MG MK ML MN MR MW MX NE NL NO NZ PL PT RO RU SD SE SG	Lesotho Lithuania Luxembourg Latvia Monaco Republic of Moldova Madagascar The former Yugoslav Republic of Macedonia Mail Mongolia Mauritania Malawi Mexico Niger Netherlands Norway New Zealand Poland Portugal Romania Russian Federation Sudan Sweden Singapore	SI SK SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU ZW	Slovenia Slovekia Senegal Swaziland Chad Togo Tajikistan Turkmenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan Viet Nam Yugoslavia Zimbabwe
---	--	---	---	---	---	--	--

15

20

25

30

35

#### Improved Biosensor

The present invention relates to an improved membrane based biosensor and to methods of improving the stability of membrane based biosensors.

Biosensors based on ion channels or ionophores contained within lipid membranes that are deposited onto conducting electrodes, where the ionophores are switched in the presence of analyte molecules have been described in International Patent Application Nos PCT/AU88/00273; PCT/AU89/00352; PCT/AU90/00025; and PCT/AU93/00509 (the disclosures of which are incorporated herein by way of reference). As these biosensors rely on changes in ion conduction through the membrane, usually mediated by an ionophore, it is important that there exists an ionic reservoir between the electrode and the lipid membrane. It is also important that the lipid membrane is at least in part linked to the reservoir and that the membrane is at least in part tethered to the conductive substrate. The stability of the substrate and the stability of the link between the reservoir and the substrate will influence the stability of the biosensor membrane plus ionic reservoir system and thus the stability of the biosensor membrane.

The present inventors have now found that the stability of the biosensor membrane can be improved by incorporating a passivating layer between the reservoir region and the conducting substrate. This passivating layer serves to increase the bonding between the reservoir forming linkers and the conductive substrate as well as serving to protect the conductive substrate surface from corrosive or electrochemical effects of the aqueous solution. This would improve the stability of the biosensor both during storage and during the actual measurement of the biosensor response on addition of analyte containing sample. A reduction in the drift of the biosensor response during analyte addition is also obtained.

Generally, formation of the reservoir functionality onto conductive substrates is through binding of individual reservoir molecules with the substrate. The present inventors have determined that by introducing binding, passivating layer between the reservoir forming molecules and the electrode the stability of the whole membrane system is improved. There is also preferably binding between the molecules making up the passivating

(

5

10

15

20

25

layer. This binding may include van der Waal's forces, hydrogen bonding forces, ionic interactions or covalent linkage. Furthermore, if a thin, passivating layer is formed between the reservoir and the conductive surface such that water and ions are restricted from interacting with the conductive substrate then corrosive effects such as electrochemical degradation are minimised and the stability of the membrane is improved. This thin passivating layer may be eletrically insulating in nature. The ionic reservoir, in this case, has a reduced contact with the conductive substrate directly and information about the ion flux into or out of the ionic reservoir can be obtained by a variety of electronic transient pulse techniques commonly used to measure the charging and discharging of resistor/capacitor circuits.

Additionally, by introducing this thin layer between the ionic reservoir and the conductive substrate, then the spacing and orientation of the ionic reservoir forming molecules is determined by the structure of the thin layer substance rather than by the surface crystal orientation of the underlying conductive substrate.

Accordingly in a first aspect the present invention consists in a membrane based biosensor, the biosensor including an electrode, a passivating layer bound to the electrode, a lipid membrane incorporating ionophores, the conductivity of the membrane being dependent on the presence or absence of an analyte, an ionic reservoir between the membrane and the passivating layer, and spanning molecules spanning the ionic reservoir the molecules being covalently attached at one end to the membrane and at the other to the passivating layer.

In a preferred embodiment the biosensor includes a plurality molecules of following general structure:

#### A-B-C-D

30 in which:

A is a hydrophobic group of between 2-50 methylene units in length;

B is a group which spans the ionic reservoir;

10

15

20

25

30

C is a group capable of hydrogen bonding, forming van der Waal's interactions, ionic bonding or covalent bonding with other molecules contained within the passivating layer; and

D is a group which binds to the conducting substrate.

In a preferred embodiment A is a hydrocarbon group of between 2-50 methylene units long, a phytanyl group, an unsaturated hydrocarbon of between 2-50 methylene groups long, a membrane spanning lipid, an archaebacterial lipid, a lipid hydrocarbon group, or a gramicidin derivative. It is presently preferred that A is a hydrocarbon group or an unsaturated hydrocarbon group of between 8-26 methylene units long or a gramicidin derivative.

In another preferred embodiment B is an oligoethylene glycol of between 4 to 20 ethylene glycol units long. Alteratively B may be repeating subunits of oligoethylene glycol of between 2 and 6 ethylene glycol units, the subunits being linked together via ester, amide or other linkages. It is highly preferred that in this arrangement that the linkages do not promote hydrogen bonding between the groups spanning the reservoir. In this regard it is preferred that the linkages are tertiary amides. As will be appreciated it is also highly preferred that linkages resistant to hydolysis such as tertiary amides are used.

In a further preferred embodiment group C of the above embodiment includes a secondary amide capable of hydrogen bonding with other amides; a hydrocarbon group capable of forming van der Waals interactions with other hydrocarbon groups, or a polymerisable group.

In a still further preferred embodiment D is a thiol, disulfide, sulfide, phosphine, silane or carboxylate.

It is further preferred that the group C in the above embodiment consists in a saturated hydrocarbon group of between 2 to 50 methylene units long, more preferably 8 to 30 methylene units long.

In a preferred embodiment the biosensor includes a plurality molecules of following general structure:

C-D

35 in which C and D are as defined above.

10

20

25

As will be recognised in the biosensor of the present invention group A will be within and form part of the membrane, group B will span the ionic reservoir and groups C and D will be within and form part of the passivating layer.

In a preferred embodiment the biosensor has a structure as shown in Figure 1.

In a further preferred embodiment the passivating layer has reduced permeability towards water and towards ions thus protecting the surface of the conductive substrate from destabilising effects due to water or ions.

In a preferred embodiment the biosensor includes a plurality molecules of following general structure:

#### A-B-C-D

15 in which:

A is a hydrophobic group such as a hydrocarbon group of between 2-50 methylene units long, a phytanyl group, an unsaturated hydrocarbon of between 2-50 methylene groups long, a membrane spanning lipid or archaebacterial lipid analog, a lipid hydrocarbon group, or a gramicidin derivative;

B is a group which spans the ionic reservoir;

C is a group that inhibits the permeation of water or ions to the conductive surface; and

D is a group capable of being attached to a conducting substrate such a a thiol, disulfide, sulfide, phosphine, silane, carboxylate or other group known to form strong interactions with surfaces.

30

35

In a preferred embodiment A is a hydrocarbon group or an unsaturated hydrocarbon group of between 8-26 methylene units long.

In another preferred embodiment B is an oligoethylene glycol of between 4 to 20 ethylene glycol units long. Alteratively B may be repeating subunits of oligoethylene glycol of between 2 and 6 ethylene glycol units, the subunits being linked together via ester, amide or other linkages. It is

10

15

20

25

highly preferred that in this arrangement that the linkages do not promote hydrogen bonding between the groups spanning the reservoir. In this regard it is preferred that the linkages are tertiary amides. As will be appreciated it is also highly preferred that linkages resistant to hydolysis such as tertiary amides are used.

In a further preferred embodiment group C includes a hydrocarbon group capable of forming van der Waals interactions with other hydrocarbon groups. The hydrocarbon group may contain a polymerisable group. Additionally the group may be functionalised at the distal end to the group D in order to modulate the function of the ion reservoir.

It is further preferred that the group C in the above embodiment comprises a saturated hydrocarbon group of between 2 to 50 methylene units long, more preferably between 8 to 30 methylene units long.

In a preferred embodiment the biosensor includes a plurality molecules of following general structure:

C-D

in which C and D are as defined above.

In a yet another preferred embodiment the passivating layer is strongly bound to the conductive substrate and the functionality that make up the ionic reservoir.

Additionally it is preferred that the group C may be functionalised at the distal end to the group D. This modification may include the incorporation of hydrophilic or hydrophobic groups, amides, alcohols, acids, amines, acrylamide or acrylate or other polymerisable groups that may be used to further stabilise the passivating layer and may be used to modulate the ion reservoir function.

It is further preferred to use molecules such as those shown below and in figures 2 and 3.

where:

n = 8 to 16

10

20

25

30

m = 1 to 10

p = 1 to 10

k = 0 to 10

R,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  = independently H, methyl, ethyl

L = hydrocarbon such as a phytanyl chain, or other lipidic

15 hydrocarbon

P = a thiol, disulfide, sulfide, or other group for attaching to metal surfaces such as gold, platinum, palladium, silver etc; or a silane or alkoxy silane or chloro silane for attaching to silica or metal oxide or other conductive surface as is known to those

skilled in the art.

In a second aspect the present invention consists in a biosensor of any aspects one or two wherein the flux of ions mediated by an ionophore through the membrane into the ionic reservoir is measured by transient electrical pulse techniques.

In order that the nature of the present invention may now be more clearly understood preferred forms thereof will now be described with reference to following non-limiting examples and Figures, in which:

Figure 1 is a schematic representation of part of the biosensor of the present invention;

Figures 2 and 3 show structures of preferred compounds used in the present invention;

Figure 4 shows the structure of DLP;

Figure 5 shows the structures of DLP-C11 and DLP-C16:

Figure 6 shows the structures of MSLOH and MSL-4XB; Figure 7 shows the structure of gramicidin (gA); Figure 8 shows the structure of gA-YY; and Figure 9 shows the structure of gA-5XB

• 5

### MATERIALS AND METHODS

#### **ABBREVIATIONS**

DLP	'Double length' phytanol, see Figure 4
PC lipid	A mixture of 1,2-di(3RS,7R,11R-phytanyl)-glycero-3-
mixture	phosphocholine and 1,2-di(3RS,7R,11R-phytanyl)glycerol in a 7:3 ratio
DLP-C11	'Double length' phytanol, attached to C11 foot, see Figure 5
DLP-C16	'Double length' phytanol, attached to C16 foot, see Figure 5
BnDS	Benzyl disulfide
MSLOH	'Membrane spanning lipid', see Figure 6
MAAD	Mercaptoacetic acid disulfide
MSL-4XB	Biotinylated membrane spanning lipid, see Figure 6
gA	Gramicidin, see Figure 7
gA-YY	Tethered gramicidin, see Figure 8
DPEPC	1,2-di(3RS,7R,11R-phytanyl)-glycero-3-phosphocholine
GDPE	1,2-di(3RS,7R,11R-phytanyl)glycerol
gA-5XB	Biotinylated gramicidin, see Figure 9
DCC	Dicyclohexylcarbodiimide
DMAP	Dimethylaminopyridine
	• • • • • • • • • • • • • • • • • • •

10

### 11-Mercaptoundecanoic acid (G)

11-Bromoundecanoic acid (20.0 g, 0.075 mol) and thiourea (6.3 g, 1.1 equiv.) were refluxed in ethanol (250 mL) overnight. Sodium hydroxide (6.3 g) in 15 water (20 mL) was added and the mixture was further refluxed for 2 hr. The solution was cooled and acidified with 1N HCl. Ethanol was evaporated under reduced pressure and the aqueous residue was extracted with  $CH_2Cl_2$ . The combined organic extracts were dried (MgSO<sub>4</sub>) and evaporated to give white powder. Yield: 15.0 g (91%) 20

 $^{1}$ H  $\delta$ (CDCl<sub>3</sub>) : 1.32 (m, 13H), 1.62 (m, 4H), 2.35 (t, 2H), 2.52 (m, 2H).

### Undecanoic acid disulphide (D)

(

11-Mercaptoundecanoic acid (G) (3.0 g, 13.7 mmol) and triethylamine (4 mL, 2.1 equiv.) were dissolved in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH(1:1) mixture (20 mL) and cooled. A solution of iodine in methanol was added until excess L was present. The solvent was evaporated under reduced pressure and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>. The solution was acidified using 3N HCl and little methanol was added to dissolve insoluble solid. The organic phase was separated, dried (MgSO<sub>4</sub>) and evaporated to yield a solid residue. The product was recrystallised once each from acetone and toluene. Yield: 1.2 g (40%)

<sup>1</sup>H δ(CDCl<sub>3</sub>): 1.26 (br, 24H), 1.62 (br, 8H), 2.37 (t, 4H), 2.65 (m, 4H).

#### 11-Mercaptoundecanol (H)

**15** 

5

10

11-Mercaptoundecanoic acid (G) (1.0 g, 4.6 mmol) was dissolved in dry THF (20 mL) and borane dimethyl sulphide (3 mL, 1.1 equiv.) was slowly added under  $N_2$  atmosphere. The mixture was stirred at room temperature for 4 hr. Water was added to the solution was extracted using ethyl acetate. The organic extract was washed with 1N HCl, water and saturated sodium bicarbonate solution successively. After drying (MgSO<sub>4</sub>), the solvent was evaporated to give a clear oil. The crude oil was purified by column chromatography [eluant: hexane/ethyl acetate (8:2)]. Yield: 0.45 g (48%)  $^{1}$ H  $\delta$ (CDCl<sub>3</sub>): 1.28 (br, 18H), 1.58 (br, 4H), 2.52 (q, 2H), 3.65 (q, 2H).

25

30

20

### Undecanol disulphide (E)

11-undecanoic acid disulphide (D) (0.5 g, 4.6 mmol) was dissolved in dry THF (20 mL) and borane dimethyl sulphide (3 mL, 1.1 equiv.) was slowly added under  $N_2$  atmosphere. The mixture was stirred at room temperature for 5 hr. Water was added to the solution was extracted using ethyl acetate. The organic extract was washed with 1N HCl, water and saturated sodium bicarbonate solution successively. After drying (MgSO<sub>4</sub>), the solvent was evaporated to give a white powder. Yield: 0.15 g (32%)

 $^{1}$ H  $\delta$ (CDCl<sub>3</sub>): 1.28 (br, 28H), 1.58 (br, 8H), 2.68 (t, 4H), 3.63 (t, 4H).

### Compound (J)

Undecanoic acid disulphide (D) (0.43, 1.0 mmol) and succinic anhydride (0.23 g, 2.0 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL). DMAP (20 mg, 0.1 equiv.) and DCC (0.41, 2.0 mmol) were added and the mixture was heated at 50 °C for 1 hr. The mixture was filtered and the filtrated was added with ethanolamine (1.5 equiv.). After stirring for further 2 hr. insoluble powder was collected and was purified by column chromatography [eluant: methanol/dichloromethane (1:9)]. Yield: 0.18 g (35%)

<sup>1</sup>H δ(CDCl<sub>3</sub>): 1.38 (br, 24H), 1.68 (br, 8H), 2.22 (t, 4H), 2.71 (t, 4H), 3.31 (t, 4H), 3.62 (t, 4H).

63 mg (0.12 mmol) of the purified disulphide was dissolved in a ethanol/water mixture (20:3) (23mL). Triphenylphosphine (47 mg, 1.5 equiv.) was added and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure and the solid residue was purified by column chromatography [eluant: methanol/CH<sub>2</sub>Cl<sub>2</sub> (8:92)]. Yield: 10 mg (16%)

<sup>1</sup>H δ(CDCl<sub>3</sub>): 1.35 (br, 12H), 1.62 (br, 4H), 2.22 (t, 2H), 2.52 (t, 2H), 3.32 (t, 2H), 3.62 (t, 2H).

#### Phytanol (1)

Phytol (5.0 g, 16.7 mmol) was stirred in ethanol (50 mL) in the presence of
 Raney nickel (1.0 g, 50% slurry in water) overnight under H<sub>2</sub> atmosphere.
 The catalyst was filtered off and the solvent evaporated to give a clear oil.
 Yield: 4.9 g (97%)
 <sup>1</sup>H δ(CDCl<sub>3</sub>): 0.87 (m, 15H), 1.25 (br, 24H), 3.70 (br, 2H).

### 30 Phytanyl succinate (2)

35

Phytanol (1) (5.0 g, 16.7 mmol) and succinic anhydride (2.5 g, 1.5 equiv.) were dissolved in pyridine (20 mL) and stirred at room temperature overnight. Pyridine was removed under reduced pressure and 0.5N HCl (100 mL) was added. The aqueous solution was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were dried (MgSO<sub>4</sub>) and evaporated to give an oil.

The crude product was purified by column chromatography [eluant: ethyl acetate/hexane (15:85)]. Yield: 5.5 g (82%)  $^{1}$ H  $\delta$ (CDCl<sub>3</sub>): 0.87 (m, 15H), 1.25 (br, 24H), 2.65 (m, 4H), 4.18 (t, 2H).

### 5 Compound (3)

(

Phytanyl succinate (2) (4.2 g, 0.01 mol), tetraethylene glycol (10.2 g, 5 equiv.) and 4-dimethylaminopyridine(DMAP) (0.13 g, 0.1 equiv.) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL). 1,3-Dicyclohexylcarbodiimide(DCC) (4.35 g, 2 equiv.) was added and the mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was purified by column chromatography [eluant: ethyl acetate/hexane (6:4)]. Yield: 2.6 g (43%)

 $^{1}$ H  $\delta$ (CDCl<sub>3</sub>): 0.85 (m, 15H), 1.25 (br, 24H), 2.65 (t, 4H), 3.67 (m, 14H), 4.12 (t, 2H), 4.27 (t, 2H).

### Compound (4)

Compound (3) (1.42 g, 2.5 mmol) and succinic anhydride (0.37 g, 1.5 equiv.)
were dissolved in pyridine (20 mL) and stirred at room temperature overnight. Pyridine was removed under reduced pressure and 1N HCl (50 mL) was added. The aqueous solution was extracted with ethyl acetate. The combined organic extracts were dried (MgSO<sub>4</sub>) and evaporated to give an oil. The crude oil was purified by column chromatography [eluant: ethyl acetate/hexane (7:3)]. Yield: 1.4 g (84%)

1H δ(CDCl<sub>3</sub>): 0.87 (m, 15H), 1.25 (br, 24H), 2.65 (m, 8H), 3.67 (m, 12H), 4.12 (t, 2H), 4.27 (t, 4H).

### Compound (5)

30

35

Compound (4) (1.4 g, 2.0 mmol) and tetraethylene glycol (2.0 g, 5 equiv.) were dissolved in  $CH_2Cl_2$  (30 mL). DMAP (30 mg, 0.1 equiv.) and DCC (0.9 g, 2 equiv.) were added and the mixture was stirred at room temperature overnight. The solution was filtered and then reduced under pressure. Water was added to the residue and extracted with  $CH_2Cl_2$ . The combined organic extracts were dried (MgSO<sub>4</sub>) and evaporated to yield an oil. The

(

crude oil was purified by column chromatography [eluant: methanol/dichloromethane (3:97)]. Yield: 1.1 g (62%)  $^{1}$ H  $\delta$ (CDCl<sub>3</sub>): 0.87 (m, 15H), 1.25 (br, 24H), 2.62 (m, 8H), 3.65 (m, 26H), 4.12 (t, 2H), 4.26 (m, 6H).

Compound (B)

Compound (5) (0.91 g, 1.1 mmol) and undecanoic acid disulphide (D) (0.23 g, 0.53 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL). DMAP (13 mg, 0.1 equiv.)
and DCC (0.24 g, 1.1 equiv.) were added and the mixture was stirred at room temperature overnight. The solution was filtered and then reduced under pressure. The crude oil was purified by column chromatography [eluant: hexane/ethyl acetate (1:9)]. Yield: 0.25 g (18%)
<sup>1</sup>H δ(CDCl<sub>3</sub>): 0.87 (m, 15H), 1.25 (br, 56H), 2.28 (t, 2H), 2.32 (t, 2H), 2.65 (m, 8H), 2.68 (t, 4H), 3.65 (m, 24H), 4.10 (m, 2H), 4.23 (m, 8H).

### Compound (A)

Further elution [hexane/ethyl acetate (1:9)] from the column of (B) gave symmetrical disulphide (A) as the second product. Yield: 0.42 g (26%)  $^{1}$ H  $\delta$ (CDCl<sub>3</sub>): 0.87 (m, 30H), 1.25 (br, 80H), 2.32 (t, 4H), 2.65 (m, 16H), 2.68 (t, 4H), 3.65 (m, 48H), 4.11 (t, 4H), 4.25 (m, 16H).

#### Compound (C)

25

30

35

20

Compound (A) (0.1 g, 0.048 mmol) was dissolved in ethanol/water mixture (20:3) (23mL). Triphenyl phosphine (0.03 g, 2.9 equiv.) was added and the mixture was stirred at room temperature for 3 days. The solvent was evaporated under reduced pressure and the residue was taken up in  $CH_2Cl_2$ . The organic solution was dried (MgSO<sub>4</sub>) and evaporated. The crude product was purified by column chromatography [eluant: hexane/ethyl acetate (1:9)]. Yield: 49 mg (49%)

<sup>1</sup>H  $\delta$ (CDCl<sub>3</sub>): 0.87 (m, 15H), 1.25 (br, 24H), 2.32 (t, 2H), 2.52 (m, 2H), 2.68 (t, 8H), 3.65 (m, 24H), 4.12 (t, 2H), 4.25 (m, 8H).

10

### 16-Iodohexadecanoic acid (6)

16-Hexadecanolide (5.0 g, 0.02 mol) was added to a mixture of HI (30 g) and acetic acid (20 g). The mixture was heated to 100 °C overnight. After cooling it was poured into a cold sodium thiosulphate solution (150 mL, 10%) and extracted using  $CH_2Cl_2$ . The combined organic extracts were dried (MgSO4) and evaporated to give a white solid. The crude product was recrystallised from diethyl ether. Yield: 4.8 g (64%)  $^{1}$ H  $\delta$ (CDCl<sub>3</sub>): 1.28 (br, 22H), 1.65 (br, 2H), 1.85 (m, 2H), 2.35 (t, 2H), 3.18 (t, 2H).

### 16-Mercaptohexadecanoic acid (N)

A mixture of 16-iodohexadecanoic acid (6) (4.0 g, 10.4 mmol) and thiourea (0.88 g, 1.1 equiv.) in ethanol (100 mL) was refluxed overnight under N<sub>2</sub> atmosphere. The solution was cooled to room temperature. Sodium hydroxide (1.0 g in 10 mL of water) wad added and the mixture was further heated for 2 hr. After cooling to room temperature 1N HCl was added and the product was extracted using CH<sub>2</sub>Cl<sub>2</sub>. The organic extract was dried and evaporated to give a white solid. Yield: 2.1 g (69%)

1H δ(CDCl<sub>3</sub>): 1.28 (br, 22H), 1.62 (br, 4H), 2.35 (t, 2H), 2.50 (t, 2H).

### Hexadecanoic acid disulphide (M)

- Method 1. 16-Mercaptohexadecanoic acid (N) (1.5 g, 5.2 mmol) and triethylamine (1.5 mL, 2.1 equiv.) were dissolved in CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH(1:1) mixture (20 mL) and cooled. A solution of methanol and iodine was added until excess I<sub>2</sub> was present. The solvent was evaporated under reduced pressure and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>. The solution was acidified using 3N HCl and little methanol was added to dissolve insoluble solid. The organic phase was separated, dried (MgSO<sub>4</sub>) and evaporated to yield a solid residue. The product was recrystallised from acetone. Yield: 0.32 g (21%)
- 35 Method 2. A mixture of 16-iodohexadecanoic acid (6) (4.0 g, 10.4 mmol) and thiourea (0.88 g, 1.1 equiv.) in ethanol (100 mL) was refluxed overnight at

room atmosphere. The solution was cooled to room temperature. Sodium hydroxide (1.0 g in 10 mL of water) wad added and the mixture was further heated for 2 hr. After cooling to room temperature 1N HCl was added and the insoluble product was collected by filtration. Yield: 2.2 g (73%)

5

 $^{1}$ H δ(CDCl<sub>3</sub>): 1.28 (br, 44H), 1.62 (br, 8H), 2.36 (t, 4H), 2.68 (t, 4H).

### Compound (L) (Figure 3)

Compound (5) (0.20 g, 0.23 mmol) and hexadecanoic acid disulphide (M) (0.12 g, 0.21 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). DMAP (5 mg, 0.1 equiv.) and DCC (53 mg, 1.1 equiv.) were added and the mixture was stirred at room temperature for 48 hr. The solution was filtered and then reduced under pressure. The crude oil was purified by column chromatography [eluant: hexane/ethyl acetate (15:85)]. Yield: 31 mg (10%) <sup>1</sup>H δ(CDCl<sub>3</sub>): 0.85 (m, 15H), 1.22 (br, 76H), 2.32 (t, 4H), 2.65 (m, 8H), 2.70 (t, 4H), 3.65 (m, 24H), 4.12 (m, 2H), 4.25 (m, 8H).

### Compound (K)

20

Further elution [hexane/ethyl acetate (1:9)] from the column of (L) gave symmetrical disulphide (K) as the second product. Yield: 0.42 g (26%)

### 16-Mercaptohexadecanol (O)

25

30

16-mercaptohexadecanoic acid (N) (0.2 g, 0.7 mmol) was dissolved in dry THF (20 mL) and borane dimethyl sulphide (1 mL, 1.1 equiv.) was slowly added under  $N_2$  atmosphere. The mixture was stirred at room temperature for 4 hr. Water was added to the solution was extracted using ethyl acetate. The organic extract was washed with 1N HCl, water and saturated sodium bicarbonate solution successively. After drying (MgSO<sub>4</sub>), the solvent was evaporated to give a white powder. Yield: 87 mg (46%)  $^1$ H  $\delta$ (CDCl<sub>3</sub>): 1.28 (br, 24H), 1.58 (br, 8H), 2.52 (q, 2H), 3.63 (t, 2H).

### 5 <u>11-(Diphenylmethylthio)-undecanoic Acid</u>

A solution of 11-mercaptoundecanoic acid (300 mg, 1.3mmol) and diphenylmethanol (255 mg, 1.3 mmol) in trifluoroacetic acid was stirred at RT, under nitrogen for 30 min. Trifluoroacetic acid was evaporated under high vacuum, the residue dissolved in ether (20 ml), washed with water (3X 20 ml), dried and evaporated. The residue was purified by chromatography (light pet. - ethyl acetate, 80: 20- 50:50) on silica to give the desired product (220 mg, 42%), m.p. (Found C, 74.55; H, 8.77. C<sub>24</sub>H<sub>34</sub>O<sub>2</sub>S requires C, 74.96; H, 8.39) ms (EI) 384.

<sup>1</sup>H nmr (CDCl<sub>3</sub>)1.22-1.29 (m, 12H, CH<sub>2</sub>), 1.58 (m, 4H, CH<sub>2</sub>), 2.34 (t, 2H, CH<sub>2</sub>-15 CO<sub>2</sub>H), 2.37 (t, 2H, CH<sub>2</sub>-S), 5.13 (s, 1H, CH-Ph), 7.20-7.44 (m, 10H, aromatic H).

### (N-Methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane)-11-(diphenylmethylthio)-undecanamide

To a solution of diphenylundecanoic amine (700 mg, 1.82mmol) and bisdimethylamino-tetraethyleneglycol diamine (2.0g, 9.1mmol) in dichloromethane (7 ml), DCC (565 mg, 2.74mmol) and DMAP (75 mg, 5 0.62mmol) dissolved in dichloromethane (3 ml) was added. The mixture stirred at RT under nitrogen for 48h. The solvent evaporated and the residue was purified by chromatography (dichloromethane: MeOH 90: 10 to remove urea salt and dichloromethane: MeOH:  $NH_3$  80: 20: 2) to give the product (390 mg, 37%) as a colourless liquid. (Found C, H, N  $C_{34}H_{54}N_2O_4S$  requires 10 C, 69.58; H, 9.27; N, 4.77) ms (EI) 587. <sup>1</sup>H nmr (CDCl<sub>3</sub>)1.22 (m, 12H, CH<sub>2</sub>), 1.58 (m, 4H, CH<sub>2</sub>), 2.38 (t, 2H, CH<sub>2</sub>- $CO_2H$ ), 2.49 (t, 2H,  $CH_2$ -S), 2.50 (s, 3H,  $NCH_3$ - $CH_2$ ), 2.83 (t, 2H,  $CH_2$ - $NCH_3$ ), 2.93 ((s) 3.04 (s), 3H, NCH<sub>3</sub>-CO), 3.54-3.64 (m, 14H, CH<sub>2</sub>-O), 5.13 (s, 1H, CH-Ph), 7.20-7.43 (m,10H, aromatic H).

[[N-Methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane]-11-(diphenylmethylthio)-undecanamide (N-methyl-N'-methyl-3,6,9-trioxa-1,11diaminoundecane) succinamide) hemisuccinamide

- To a solution of (N-methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane)-20 11-(diphenylmethylthio)-undecanamide (200 mg, 0.34mmol) and bis-(Nmethyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane) hemisuccinamide (572 mg, 1.36mmol) in dichloromethane (10 ml), DCC (110 mg, 0.53mmol) and DMAP (13 mg, 0.10mmol) dissolved in dichloromethane (4 ml) was
- added. The mixture stirred at RT under nitrogen for 24h. The white ppt. Of 25 the urea was filtered and washed with dichloromethane. More dichloromethane (50 ml) was added and washed with water (2X30 ml), brine (30 ml), dried and evaporated. The residue was then purified by hplc(4% MeOH, 0.5% acetic acid in dichloromethane) on a semi prep column with
- retention time (29 min) to give the product (160 mg,47%) a colourless liquid. 30 (Found C, H, N  $C_{52}H_{84}N_4O_{12}S$  requires C,; H,; N,) ms (ESI) 989 and M+Na 1012.
  - <sup>1</sup>H nmr (CDCl<sub>3</sub>) 1.25 (m, 12H, CH<sub>2</sub>), 1.57 (m, 4H, CH<sub>2</sub>), 2.33 (m, 2H, CH<sub>2</sub>-CO<sub>2</sub>H), 2.37 (m, 2H, CH<sub>2</sub>-S), 2.61-2-67 (m, 8H, CO-CH<sub>2</sub>-CH<sub>2</sub>-CO), 2.95,
- 2.97,3.06, 3.09, 3.11 ((s) 15H, NCH<sub>3</sub>-CO), 3.55-3.61 (m, 32H, CH<sub>2</sub>-O), 5.14 (s, 35 1H, CH-Ph), 7.16-7.41 (m,10H, aromatic H).

( -

(((N-Methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane)-11-(diphenylmethylthio)-undecanamide (N-methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane) succinamide) N-methylphytanamine) succinamide

To a solution of (N-methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane)11-(diphenylmethylthio)-undecanamide (100 mg, 0.17mmol) and (Nmethylphytanamine (N-methyl-N'-methyl-3,6,9-trioxa-1,11diaminoundecane) succinamide) hemisuccinamide (160 mg, 0.22mmol) in
dichloromethane (10 ml), DCC (52 mg, 0.25mmol) and DMAP (6 mg,
0.05mmol) dissolved in dichloromethane (3 ml) was added. The mixture
stirred at RT under nitrogen for 24h. The solvent evaporated and the residue
was purified by chromatography (DCM: MeOH 95: 5) to give the product
(180 mg, 83%) as a colourless liquid. (Found C, H, N C<sub>73</sub>H<sub>127</sub>N<sub>5</sub>O<sub>11</sub>S requires
C,; H,; N,) ms (ESI) 1282 and M+Na 1305.

<sup>1</sup>H nmr (CDCl<sub>3</sub>) ).82-1.25 (m, 55H, CH<sub>2</sub>), 1.59 (m, 4H, CH<sub>2</sub>), 2.33 (t, 2H, CH<sub>2</sub>-CO<sub>2</sub>H), 2.37 (t, 2H, CH<sub>2</sub>-S), 2.65-2-68 (m, 8H, CO-CH<sub>2</sub>-CH<sub>2</sub>-CO), 2.89, 2.95, 2.99, 3.04, 3.09 ((s) 15H, NCH<sub>3</sub>-CO), 3.54-3.64 (m, 34H, CH<sub>2</sub>-O), 5.13 (s, 1H, CH-Ph), 7.20-7.43 (m, 10H, aromatic H).

[[[N-Methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane]-11-thioundecanamide (N-methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane) succinamide) N-methylphytanamine) succinamide

A solution of (((N-methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane)-11-(diphenylmethylthio)-undecanamide (N-methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane) succinamide) N-methylphytanamine) succinamide (100 mg, 0.78mmol) and phenol (144 mg) in trifluoroacetic acid (1 ml), was stirred at RT under nitrogen. After 6h (the hplc indicated the disappearance of the starting material) the trifluoroacetic acid was removed under high vacuum and the residue was purified by hplc (dichloromethane: methanol 93:7) to give a single peak of the product (39 mg, 45%) a colourless liquid. (Found C, H, N C<sub>80</sub>H<sub>117</sub>N<sub>5</sub>O<sub>11</sub>S requires C,; H,; N,) ms (CI) 1117 (M+1) <sup>1</sup>H nmr (CDCl<sub>3</sub>) 82-1.25 (m, 55H, CH<sub>2</sub>), 1.59 (m, 4H, CH<sub>2</sub>), 2.35 (m, 2H, CH<sub>2</sub>-CO<sub>2</sub>H), 2.60 (m, 2H, CH<sub>2</sub>-S), 2.65-2-68 (m, 8H, CO-CH<sub>2</sub>-CH<sub>2</sub>-CO), 2.89, 2.95, 2.99, 3.04, 3.09 ((s) 15H, NCH<sub>3</sub>-CO), 3.54-3.64 (m, 34H, CH<sub>2</sub>-O).

10

15

[[[N-Methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane]-11-(diphenylmethylthio)-undecanamide (N-methyl-N'-methyl-3,6,9-trioxa-1,11diaminoundecane) succinamide) gramicidin-lysine) succinamide To a solution of ((N-methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane)-11-(diphenylmethylthio)-undecanamide (N-methyl-N'-methyl-3,6,9-trioxa-5 1,11-diaminoundecane) succinamide) hemisuccinamide (40 mg, 0.04mmol) and gramicidin lysine (30 mg, 0.02mmol) in dichloromethane (3 ml), DCC (10.5 mg, 0.05mmol) and DMAP (6 mg, 0.05mmol) dissolved in dichloromethane (1 ml) was added. Pyridine (0.5 ml) was added to dissolve the suspension. The mixture stirred at RT under nitrogen for 72h. The 10 solvent evaporated and the residue purified by reverse phase hplc gradients (A: water B: methanol 50 to 70 to 100 over 60 min) to give the product (8 mg,17%) as fraction 4 with retention time 52 min as white precipitate. ms (ESI) M+Na 2961.

15

(((N-Methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane)-11-thioundecanamide (N-methyl-N'-methyl-3,6,9-trioxa-1,11-diaminoundecane) succinamide) gramicidin-lysine) succinamide

A solution of diphenyl undecanoicTEG-Succ-TEG-Succ-gALys (9 mg, 0.003mmol) and phenol (60 mg) in trifluoroacetic acid (0.4 ml), was stirred at RT under nitrogen. After 3h (the hplc indicated the disappearance of the starting material) the trifluoroacetic acid was removed under high vacuum and the residue was purified by hplc (gradients (A: water B: methanol 50 to 70 to 100 over 30 min) to give the product (1.4 mg, 18%) with retention time 27.53 min as white precipitate. ms (ESI) M+Na 2795.

10

15

30

35

Bis-dimethylamino membrane spanning lipid [MSL dimethyldiamine] A solution of the C<sub>38</sub>-dimesylate (750mg, 0.5mmol) was added to anhydrous methylamine (19mL) at -12°C. The reaction mixture, in a pressure tube, was allowed to warm to room temperature and was gently stirred for 48 h. The excess methylamine was removed and the residue was stirred with excess anhydrous potassium carbonate in dichloromethane for 3h. The mixture was filtered through barium carbonate and the solvent removed to give a waxy solid. Chromatography on silica gel with 1% ammonia and 4% methanol in dichloromethane followed by 1% ammonia and 8% methanol in dichloromethane as eluent gave the C<sub>38</sub>-diamine (423mg, 62%) as a white waxy solid.

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 0.80-1.89 (130H, m, aliphatics), 2.49 (6H, s, NMe), 2.76 (4H,

'H nmr (CDCl<sub>3</sub>) 0.80-1.89 (130H, m, aliphatics), 2.49 (6H, s, NMe), 2.76 (4H, m, CH<sub>2</sub>N), 3.36-3.78 (14H, m, OCH and OCH<sub>2</sub>), 3.98 (4H, t,  $^3$ J 6.5 Hz, CH<sub>2</sub>OAr), 6.95 and 7.46 (8H, AA'BB', biphenyl).  $^{nl}/_{\theta}$  687.5 (M<sup>2+</sup>) (M<sup>+</sup> requires 1374.3).

### Example 1 Bilayer: comparison of bottom layer

A freshly prepared evaporated gold thin film (1000A) on glass with chromium under-layer (50 A) was clamped in a containment vessel. Ten microlitres of ethanol solution of compound DLP 1 mM was added into the vessel thus covering the gold electrode. After one hour the electrode was washed with ethanol and dried using nitrogen gas. Five microlitres of PC lipid mixture in ethanol with ionophore valinomycin (200:1)was added to the electrode. The electrode was rinsed then three times with 0.5 mL of 0.1M saline solution. Impedance spectra were obtained before and after 0.1M potassium challenge.

Another freshly prepared evaporated gold thin film (1000A) on glass with chromium under-layer (50 A) was clamped in a containment vessel. Ten microlitres of ethanol solution of compound B 1 mM was added into the vessel thus covering the gold electrode. After one hour the electrode was washed with ethanol and dried using nitrogen gas. Five microlitres of PC lipid mixture in ethanol with ionophore valynomicin (200:1)was added to the electrode. The electrode was rinsed then three times with 0.5 mL of

15

20

0.1M saline solution. Impedance spectra were obtained before and after 0.1M potassium challenge.

Yet another freshly prepared evaporated gold thin film (1000A) on glass with chromium under-layer (50 A) was clamped in a containment vessel. Ten microlitres of ethanol solution of compound L 1 mM was added into the vessel thus covering the gold electrode. After one hour the electrode was washed with ethanol and dried using nitrogen gas. Five microlitres of PC lipid mixture in ethanol with ionophore valynomicin (200:1)was added to the electrode. The electrode was rinsed then three times with 0.5 mL of 0.1M saline solution. Impedance spectra were obtained before and after 0.1M potassium challenge.

Impedance at 1kHz, 1 Hz, phase shift minimum and frequency at phase shift minimum for DLP, DLP-C11 and DLP-C16 based bilayers: after KCl challenge are shown in the Table below.

2			Z ,		in psi	min frequency
kOhm		kOhm			00	Hz
11	cHz		1 Hz deg			
1.86	3.5%	158	12 %	39	4 %	10-20
1.94	4 %	338	7 %	50	3 %	10
2.34	4 %	497	22 %	57	6 %	10
	1.86 1.94	1 kHz  1.86 3.5%  1.94 4 %	kOhm kOhm 1 kHz  1.86 3.5% 158  1.94 4 % 338	kOhm     kOhm       1 kHz     1 Hz       1.86     3.5%     158     12 %       1.94     4 %     338     7 %	kOhm  1 kHz  1 Hz  1.86  3.5%  158  12 %  39  1.94  4 %  338  7 %  50	kOhm     kOhm       1 kHz     1 Hz     deg       1.86     3.5%     158     12 %     39     4 %       1.94     4 %     338     7 %     50     3 %

Impedances at 1 kHz and 1 Hz and phase shift minimum increase when the monolayer thickness increases from BnDS to C11 to C16 molecules. The frequency minimum on the other hand is only weakly affected by the change.

### Example 2 Stability: monolayers

# 2.1 Stability of C11 and C16 DLP and DLP in $H_2O$ at 50 °C using X-ray Photoelectron Spectroscopy (XPS)

#### Method:

A freshly prepared evaporated gold thin film (1000A) on glass with chromium under-layer (50 A) was immersed into a vessel containing ethanolic solution 1mM of compound the vessel thus covering the gold electrode. After one hour the electrode was washed with ethanol and dried using nitrogen gas and measured with XPS. The samples were immersed in deionised H<sub>2</sub>O for 1hr at 50°C and measured again by XPS. The regions of interest were C1s, O1s and Au 4f. The values quoted below are the average of two measurements on one sample.

15

20

10

5

Table 1: Carbon and Oxygen, % (Integrity of monolayer)

Monolayer	C% before after		O% before after		ratio(C/O) before after	
C16-S-S-C16-DLP	78.4	78.9	21.6	21.1	3.63	3.73
C11-S-S-C11-DLP	77.7	77.7	22.3	22.3	3.48	3.48
DLP (standard)	<i>7</i> 5	76	25	24	3	3.16

Table 2: Carbon and Au % (surface coverage)

Monolayer	C (are before	•	Au (ar before	ea) after	Au/C befor	
C16-S-S-C16-DLP	5377	6012	20848	22826	3.88	3.80
C11-S-S-C11-DLP	5511	5637	24114	26751	4.38	4.74
DLP (standard)	5454	5319	47854	56988	8.77	10.7

(

Table 3: 0%: Au % (surface coverage)

Monolayer	O (area	) after	Au (are before	a) after	Au/O before after	
C16-S-S-C16-DLP	4015	4073	20848	22826	5.20	5.59
C11-S-S-C11-DLP	4012	4103	24114	26751	6.0	6.52
DLP (standard)	4635	4066	47854	56988	10.3	14.0

Table 1 shows that the ratio between the carbon and oxygen content of various DLP's monolayers. The variation is within the experimental error indicating that the molecules did not disintegrate and if any desorption occurred it would be take place in the form of disulfide bond breaking from the Au surface.

Table 2 . shows a comparison of carbon and Au content of various DLP's monolayers before and after 50°C ethanol immersion. The result show that C16-DLP is the least effected by immersion of H<sub>2</sub>O at 50 °C, C11-DLP is effected slightly and the greatest effect seen with DLP.

Table 3. shows a comparison of oxygen content of various DLP's monolayers before and after 50°C ethanol immersion. The result show that C16-DLP is the least effected by immersion of H<sub>2</sub>O at 50 °C, C11-DLP is effected slightly and the greatest effect seen with DLP. This suggests that the further the monolayer (i.e. the longer molecule) is from the gold surface the more protected it remains.

20

5

10

15

### Stability of C11 and C16 DLP and DLP in Ethanol at 50 °C using 2.2 XPS

Method:

Au thin film were sputtered onto Si substrate with Ti interlayer. The 25 samples were immersed for 1hr at room temperature and measured with XPS. Then the samples were immersed in ethanol for 1hr at 50°C and measured again by XPS. The regions of interest were C1s, O1s and Au 4f. The values quoted below are the average of two measurements on one sample 30

Table 4: Monolayer composition and Au percentage detected.

Monolayer	C% befor	C% before after		O% before after		:e
C16-S-S-C16-DLP	67.7	67.4	22.2	22.0	after	10.6
C11-S-S-C11-DLP	64.2	64.4	20.5	19.1	15.3	16.5
DLP (standard)	65.0	63	20.0	18.9	15.0	18.1
C18-thiol	54.4	51.3	-	-	45.6	48.7

Table 4 shows a trend where the sample immersed in ethanol at 50°C the Au percentage increased indicating a desorption of the outer layer. Also, this effect appeared to be dependent on the length of the molecules, the longer 5 the molecules the less the increase in Au percentage is observed.

Table 5: Carbon and Oxygen percentage of DLP's monolayers

Monolayer	C%	C% before/		O% before / after		e
C16-S-S-C16-DLP	77.8	78	22.2	22.0	/after	Ţ
C11-S-S-C11-DLP	75.8	77.1	24.2	22.9	3.13	3.55
DLP (standard)	76.5	76.9	23.5	23.1	3.26	3.33

The ratio of carbon to oxygen is a measure of monolayer integrity. The ratio 10 for each of the monolayer do not changes significantly suggesting that the molecules do not disintegrate.

Table 6 Carbon and gold of DLP's monolayers (surface coverage)

Monolayer C (area) Au (area) Au/C ratio before after before after before after C16-S-S-C16-DLP 5948 5807 22849 23385 3.84 4.02 C11-S-S-C11-DLP 5216 5163 24641 28138 4.72 5.5 DLP (standard) 1766 812 8176 4620 4.63 5.69 c18-thiol 950 534 16017 10473 16.9 19.6

10

15

20

25

Table 7 Oxygen and gold of DLP's monolayers (surface coverage)

Monolayer	O (intensity) before after		Au (intensity) before after		Au/O ratio before after	
C16-S-S-C16-DLP	4331	4165	22849	23385	5.28	5.61
C11-S-S-C11-DLP	4212	4115	24641	28138	5.85	6.84
DLP (standard)	1384	755	8176	4620	5.91	6.2

### Example 3 Bilayer: transient

A freshly prepared evaporated gold thin film (1000A) on glass with chromium under-layer (50 A) was clamped in a containment vessel. Ten microlitres of ethanol solution of compound DLP 1 mM was added into the vessel thus covering the gold electrode. After one hour the electrode was washed with ethanol and dried using nitrogen gas.

Five microlitres of PC lipid mixture in ethanol with ionophore valynomicin (200:1)was added to the electrode. The electrode was rinsed then three times with 0.5 mL of 0.1M saline solution. A transient technique was used to measure sensor response.

A train of potential pulses was applied to the electrode using a commercial potentiostat, EG&G 263M Princeton with AMLAB computer control data acquisition system (pulse duration 50 msec, delay between pulses 950 msec). The currect response of the system was measured before and after 0.1M potassium challenge. The shape of the current response changes upon changes in the concentration of potassium ions. The current can be fitted using two exponential function with time constants tau1 and tau2. The electrolyte concentration can be correlated with one of the time constant that is related with the membrane conductance.

### Example 4 Ferritin gating experiments.

( ... i.

#### Aim:

To demonstrate that a ferritin gating response can be achieved with membrane systems incorporating C11-amide gAYY.

### Method:

1<sup>st</sup> layer solutions:

10

IJ AM300		
DLP	10mM	1500րL
MSLOH	1mM	225µL
MAAD	10mM	225µL 750µL
MSL4XB	0.1mM	730µL 11.25µL
gAYY	$0.01 \mathrm{mg/mL}$	11.23μL 579μL

+ 46.9mL EtOH

15 ii) 2,000:1, C11-DLP/C11-amide gAYY

DLP-C11		
,	10mM	25µL
$HS(CH_2)_{10}CO_2H$	1mM	20,22
	11111/1	125µL
C11-amide gAYY	3.61µM	
ŭ	σιστρινί	34.7µL

+ 815.3µL EtOH

iii) 5,000:1, C11-DLP/C11-amide gAYY;

DLP-C11	10mM	257
HS(CH <sub>2</sub> ) <sub>10</sub> CO <sub>2</sub> H	1mM	25μL
C11-amide gAYY	<del>-</del>	125µL
orr amide Surr	3.61µM	138 GuT

20

+ 711.4μL EtOH

## Standard, hand assembled blocks were used.

### 1<sup>st</sup> layer formation:

Fresh slides were obtained from the evaporator and used immediately.

Slides were assembled in blocks and to each cell  $40\mu L$  of  $1^{st}$  layer solution 5 added.

Blocks were incubated with 1st layer solution for ~ 2 - 3 hours at room temperature, whereupon excess solution was removed, and each cell rinsed thoroughly with ethanol from a wash bottle. Residual ethanol was removed by vigorous shaking and blocks inverted and air-dried.

2<sup>nd</sup> layer formation:

 $5 \times 10^4 / 4$  gA-5XB conducting membranes were assembled using 10 mM DPEPC:GDPE 7:3. After assembly membranes were challenged with;

- $5\mu$ L, 0.1mg/mL Streptavidin, PBS wash(3x) i)
- $5\mu L$ , 0.05 mg/mL anti-Ferritin Fab', PBS wash (3x) ii) 15
  - 100μL, 100pM Ferritin (ii

N.B.: 2 different substrates were used; (i.e. deposition process - evaporation)

- polycarbonate / Cr + Au i)
- glass / Cr + Au ii) 20

Table 1: Comparison of Ferritin Gating responses (50pM final conc.)

_ T H2	1 Hz Intercent	_	Two on on the	٤	.;;	-					
	(kHz)		r Karz intercept (kHz)	rred Phas	rreg. Min. Phase (Hz)	~ ·	NMS [-/ks]		Tau	8	% Gating
Av.	C.V.	Av.	C.V.	Av.	C.V.	Av.	C.V.	Av.	(sec.)	Av	Λ )
1								-			;
- 1	3.6	7									
		0.7	4.8	78 18	20.1	1.231	9.9	528	14.7	52	3.9
	10.7	2	11	413	100.6	0.651	22.4	795	9.2	51	12.4
-	5	2	5.6	37	33	0.669	24.1	785	26	42	9.5
+											
- -	22.8	,									
	0.03	#: 	7.7	43.7	10.1	1.671	7.7	247	10.4	43	9.5
	18.8	2.1	7.7	23.9	16.1	1.325	17.2	242	13.3	36.5	14
┼	3.4	1.7	5.2	16.7	163	1 297	077				
						/03-1	14.8	290	9.1	40	9.6
┼-	3.9	1.8	3.0	27.0							
	}			31.8	8.1	0.976	5.8	517	8	49.3	3.3
-	2.3	1.9	3.4	42.3	12.4	0 581	6	300			
								1391	16	53	14.5

### Conclusion:

A ferritin gating response can be elicited from membranes assembled with C11-amide modified gAYY. From the 3 different data sets, the magnitude of the gating response is comparable to the standard AM300 system, however there is some variation in the speed of response and initial membrane conductivity.

# Example 5 Stability trials testing C11-amide gAYY.

### Aim:

5 To determine whether the inclusion of a C11-amide modified gAYY improves membrane stability upon storage.

### Method:

- 10 1<sup>st</sup> layer solutions:
  - i) "AM300"

DLP	10mM	1500µL
MSLOH	1mM	225µL
MAAD	10mM	225µL 750µL
MSL4XB	0.1mM	750μL 11.25μL
gAYY	0.01mg/mL	11.25µL 579µL
+ 807.5µL EtOH		379µL

15

ii) 2,000:1 DLP-C11/C11-ester gAYY;

DLP-C11	40	
_ <del>_</del>	10mM	25µL
$HS(CH_2)_{10}CO_2H$	1mM	125µL
C11-ester gAYY	0.01mg/mL	•
+ 46 0ml FtOU		42.3µL

+ 46.9mL EtOH

20 iii) 5,000:1, C11DLP/C11-amide gAYY;

C11-amide gAYY	3.61µM	138.6µL
	<b></b>	125µL
HS(CH <sub>2</sub> ) <sub>10</sub> CO <sub>2</sub> H	1mM	•
DLP-C11	10mM	25µL

+ 711.4 $\mu$ L EtOH

10

Manual assembled blocks were used. Substrate: polycarbonate / Cr + Au (Evaporated)

### 1<sup>51</sup> layer formation:

Fresh slides were obtained from the evaporator and used immediately. Slides were assembled in blocks and to each cell  $40\mu L$  of  $1^{st}$  layer solution added.

Blocks were incubated with 1st layer solution for - 2 - 3 hours at room temperature, whereupon excess solution was removed, and each cell rinsed thoroughly with ethanol from a wash bottle. Residual ethanol was removed by vigorous shaking and blocks inverted and air-dried.

### 2<sup>nd</sup> layer formation:

Sealed, non-conducting membranes were prepared using 10mM DPEPC/GDPE 7:3. 15

Blocks were stored at room temperature in PBS and the impedance measured at 0.1Hz at periodic intervals.

#### Results: 20

### Averaged Impedance Plots:

The averaged impedance plots of the test system (i.e. with the inclusion of C11-amide gAYY, 5,000:1) and 2 controls; AM300 and a 25 membrane system with C11-ester analogues only were determined. These membranes were stored in PBS at room temperature, with the first 7 days of data being shown.

The AM300 showed a rapid increase in membrane leakage after 7 days storage. In comparison, when both the C11-SH passivity layer and 30 amide linkages are incorporated into the tethered gramicidin component (i.e. C11-amide gAYY), the membrane remained well sealed, with no change in stability after 7 days storage.

Membranes assembled from C11-ester analogues only showed improvement over AM300 but were not as stable as the C11-amide gAYY. Similar results were obtained after 3 weeks and 5 weeks storage.

### 5 Conclusion:

10

15

20

25

It has been shown that a stable, fully hydrated bilayer membrane can be achieved by improving the chemical stability within the reservoir region. When membranes are assembled with a C11-amide modified tethered gramicidin, membranes are stable for at least 5 weeks at room temperature with no significant loss of sealing ability.

The inclusion of a passivity layer (C11-SH tether) improves the Au-S attachment, while the introduction of amide linkages are more resistant to hydrolysis. These improvements minimise the ability of the tethered gramicidin to detach from the substrate surface, allowing it to transfer between membrane layers.

This result represents the most significant advance as it overcomes the rapid degradation / leakage associated with the short term stability of current membrane based biosensor systems.

The membrane stability with this new architecture may be further enhanced by minimising degradation due to mechanical leakage. The use of a slide laminate will help to define the cell area in a more controlled manner and reduce the likelihood of membrane leakage underneath the teflon inserts of the current block assembly.

It is also important to note that the membrane stability achieved is in the absence of any membrane spanning component in the bilayer. Further improvements in stability would most likely be achieved with the inclusion of a transmembrane lipid.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

(----

5

#### Claims:-

- 1. A membrane based biosensor, the biosensor including an electrode, a passivating layer bound to the electrode, a lipid membrane incorporating ionophores, the conductivity of the membrane being dependent on the presence or absence of an analyte, an ionic reservoir between the membrane and the passivating layer, and reservoir spanning molecules spanning the ionic reservoir the molecules being covalently attached at one end to the membrane and at the other to the passivating layer.
- 2. A membrane based biosensor as claimed in claim 1 in which the biosensor includes a plurality molecules of following general structure:

#### A-B-C-D

15 in which:

A is a hydrophobic group of between 2-50 methylene units in length;

B is a group which spans the ionic reservoir;

C is a group capable of hydrogen bonding, forming van der Waal's interactions, ionic bonding or covalent bonding with other molecules within the passivating layer; and

D is a group which binds to the conducting substrate.

25

30

- 3. A membrane based biosensor as claimed in claim 2 in which A is a hydrocarbon group of between 2-50 methylene units long, a phytanyl group, an unsaturated hydrocarbon of between 2-50 methylene groups long, a membrane spanning lipid, an archaebacterial lipid, a lipid hydrocarbon group, or a gramicidin derivative.
- 4. A membrane based biosensor as claimed in claim 3 in which A is a hydrocarbon group or an unsaturated hydrocarbon group of between 8-26 methylene units long or a gramicidin derivative.
- 5. A membrane based biosensor as claimed in any one of claims 2 to 4 in which B is an oligoethylene glycol of between 4 to 20 ethylene glycol units long.

- 6. A membrane based biosensor as claimed in any one of claims 2 to 4 in which B is repeating subunits of oligoethylene glycol of between 2 and 6 ethylene glycol units, the subunits being linked together via ester, amide or other linkages.
- 5 7. A membrane based biosensor as claimed in claim 6 in which linkages do not promote hydrogen bonding between the groups spanning the reservoir.
  - 8 A membrane based biosensor as claimed in claim 6 in which the linkages are tertiary amides.
- 9. A membrane based biosensor as claimed in claim 2 in which C includes a secondary amide capable of hydrogen bonding with other amides; a hydrocarbon group capable of forming van der Waals interactions with other hydrocarbon groups, or a polymerisable group.
- 10. A membrane based biosensor as claimed in claim 9 in which C is a
   15 saturated hydrocarbon group of between 2 to 50 methylene units long, more preferably 8 to 30 methylene units long.
  - 11. A membrane based biosensor as claimed in claim 2 in which D is a thiol, disulfide, sulfide, phosphine, silane or carboxylate.
- 12. A membrane based biosensor as claimed in any one of claims 1 to 11
  20 in which the biosensor includes a plurality molecules of following general structure:

C-D

in which:

25

C is a group capable of hydrogen bonding, forming van der Waal's interactions, ionic bonding or covalent bonding with other molecules within the passivating layer; and

D is a group which binds to the conducting substrate.

- 30 13. A membrane based biosensor as claimed in claim 12 in which C includes a secondary amide capable of hydrogen bonding with other amides; a hydrocarbon group capable of forming van der Waals interactions with other hydrocarbon groups, or a polymerisable group.
- 14. A membrane based biosensor as claimed in claim 11 or claim 12 in which C is a saturated hydrocarbon group of between 2 to 50 methylene units long, more preferably 8 to 30 methylene units long.

(

- 15. A membrane based biosensor as claimed in claim 12 in which D is a thiol, disulfide, sulfide, phosphine, silane or carboxylate.
- 16. A membrane based biosensor as claimed in claim 2 in which the molecule is of the formula:-

5

10 where: n = 8 to 16

m = 1 to 10

p = 1 to 10

k = 0 to 10

R,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  = independently H, methyl, ethyl

L = hydrocarbon such as a phytanyl chain, or other lipidic hydrocarbon

P = a thiol, disulfide, sulfide, or other group for attaching to metal surfaces such as gold, platinum, palladium, silver etc; or a silane or alkoxy silane or chloro silane for attaching to silica or metal oxide.

20


15

- 17. A membrane based biosensor as claimed in any one of claims 1 to 16 in which the passivating layer has reduced permeability towards water and towards ions thus protecting the surface of the conductive substrate from destabilising effects due to water or ions.
- 25 18. A membrane based biosensor as claimed in any one of claims 1 to 17 in which the reservoir spanning molecules are atached to the passivating layer via an ester, ether or amide linkage, preferably by an amide linkage, most preferably a secondary amide.
- 19. A membrane based biosensor as claimed in any one of claims 1 to 18
   30 in which the reservoir spanning molecules are atached to the lipid membrane

via an ester, ether or amide linkage, preferably by an amide linkage, most preferably a secondary amide.


1/5

Figure 1



0

Figure 3



L

ĸ

М

Ν




Figure 4

Figure5

Figure 6




Figure 7

Figure 8

Figure 9

### INTERNATIONAL SEARCH REPORT

International Application No.

	4	l	Application No.
A.	CLASSIFICATION OF SUBJECT MAT	TER	PCT/AU 98/00423
Int Cl6:	G01N 27/327, 27/333		
According	to International Patent Classification (IPC) or t	O both patient along	-
В.	FIELDS SEARCHED	PC	
Minimum de IPC: G01	ocumentation searched (classification system follower N 27/327, 27/333	ed by classification symbols)	
Documentati AU: IPC	on searched other than minimum documentation to t	the extent that such documents are incl	uded in the fields searched
CAPLUS:	ta base consulted during the international search (na embrane and (ion or ionaph:) and passivat: (biosensors or bioelectrodes) and (membran Database: biosensor and membrane and pas		e, search terms used)
<del></del>	DOCUMENTS CONSIDERED TO BE RELEV		
Category*	Citation of document, with indication, when	e appropriate, of the relevant passa	ges Relevant to claim No
WO 92/17788 (AUSTRALIAN MEMBRA RESEARCH INSTITUTE 15 October 199 entire document  Biosensors and Bioelectronics (1995) vol. "Tetracyanoquinodimethane mediated gluc alkanethiol/phospolipid bilayer" pages 664 entire document		Pandey et al.	1-19
		574 accumonii	1-19
X	Further documents are listed in the continuation of Box C	X See patent fam	uly annex
Speci	al categories of cited documents:		
not come not come intern docum or white another docum exhibit docum date by	it later than the priority date claimed	"X" document of particular relevant inventive step when the document of particular relevant inventive step when the document of particular relevant document of particular relevant	cory underlying the invention ice; the claimed invention cannot be considered to involve an ient is taken alone iet; the claimed invention cannot ventive step when the document is ier such documents, such a person skilled in the cer
docum not co rearlier intern docum or whi anothe docum exhibi docum date bu	r document but published on or after the attional filing date sent which may throw doubts on priority claim(s) ch is cited to establish the publication date of a citation or other special reason (as specified) sent referring to an oral disclosure, use, tion or other means ent published prior to the international filing.	"X" document of particular relevant be considered novel or cannot inventive step when the document of particular relevant be considered novel or cannot inventive step when the document of particular relevant be considered to involve an inventive with one or more office combination being obvious to a document member of the same	it with the application but cited to cory underlying the invention ace; the claimed invention cannot be considered to involve an ment is taken alone ace; the claimed invention cannot ventive step when the document is her such documents, such a person skilled in the art patent family
A" docum not co earlier intern docum or whit anothe docum exhibi docum date bu tte of the actum July 1998 me and maili JSTRALIAN BOX 200	r document but published on or after the attional filing date tent which may throw doubts on priority claim(s) ch is cited to establish the publication date of a citation or other special reason (as specified) tent referring to an oral disclosure, use, tion or other means ent published prior to the international filing at later than the priority date claimed all completion of the international search and completion of the isolated part and completion and completion of the isolated part and com	"X" document of particular relevant be considered novel or cannot inventive step when the document of particular relevant be considered novel or cannot inventive step when the document of particular relevant be considered to involve an inventive with one or more other combination being obvious to a document member of the same  Date of mailing of the international — 5 AUG  Authorized officer	it with the application but cited to cory underlying the invention ace; the claimed invention cannot be considered to involve an ment is taken alone ace; the claimed invention cannot ventive step when the document is her such documents, such a person skilled in the art patent family
A" docum not co earlie intern docum or whi anothe O" docum date by docum date by the of the actus JULY 1998 Imme and maili JUSTRALIAN DEOX 200 DDEN ACT	r document but published on or after the attional filing date tent which may throw doubts on priority claim(s) ch is cited to establish the publication date of a citation or other special reason (as specified) tent referring to an oral disclosure, use, tion or other means ent published prior to the international filing at later than the priority date claimed all completion of the international search and completion of the isolated part and completion and completion of the isolated part and com	"X" document of particular relevant be considered novel or cannot inventive step when the document of particular relevant be considered to involve an inventive with one or more other combination being obvious to a document member of the same  Date of mailing of the international	it with the application but cited to cory underlying the invention ace; the claimed invention cannot be considered to involve an ment is taken alone ace; the claimed invention cannot ventive step when the document is her such documents, such a person skilled in the art patent family

## INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 98/00423

TERNA'I	TONAL SEARCH REPORT	CT/AU 98/00423	ł
•	CONCIDEDED TO BE RELEVANT		1
C(Continuat Category*	Citation of document, with indication, where appropriate, of the relevant pass	Relevant to claim No.	
	EP 441 120 A2 (YEDA RESEARCH AND DEVELOPMENT COMPANY, L 14 August 1991 page 3 line 51 - page 4 line 6; figure 2	TD)	
Y	WO 97/01092 (AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RI INSTITUTE) 9 January 1997 Pages 2-3; figure 4	ESEARCH 1-19	

#### INTERNATIONAL SEARCH REPORT

#### Information on patent family members

International Application No. PCT/AU 98/00423

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
wo	92/17788	AU	14657/92	CA	2106966	EP	639269
		US	5401378				
EP	441120	AU	69245/91	CA	2033776	IL	93020
		JР	6090736	US	5204239		
wo	97/01092	AU	59926/96	EP	838028		

END OF ANNEX

THIS PAGE BLANK (USPTO)

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

#### IMAGES ARE BEST AVAILABLE COPY.

□ OTHER: \_\_\_\_\_

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)